Catheter Resistance Monitoring to Predict Catheter-Associated Adverse Events in Children and Adolescents (CaRMA): A Feasibility Study

In order for our site to display correctly you will need a newer version of your web browser.

Currently we test and support the following browsers:

FireFox version 3.0 and above (Windows and Mac)
Safari version 5.0 and above (Windows and Mac)
Internet Explorer version 7.0 and above (Windows)

Please note that this is not intended to be an exhaustive list of browsers that support web standards, nor a test of browser compliance, nor a side-by-side comparison of various manufacturers’ browsers.

Research

Infectious Diseases

Back to Current Clinical Trials

Non-Therapeutic Protocol

CaRMA: Catheter Resistance Monitoring to Predict Catheter-Associated Adverse Events in Children and Adolescents (CaRMA): A Feasibility Study

Type of Protocol/Clinical Study

Associated Infectious Diseases Studies

Description

Young people with cancer require intravenous (IV) treatment using long-term ‘central-lines’ for medication, and laboratory tests. Central-lines can develop blockages (occlusion) and cause infections or clots in blood vessels. If partial occlusion can be recognized, preventive treatment might prevent these complications.

To find out if weekly central-line resistance monitoring (CRM) can identify partial occlusion, 35 St. Jude patients will have weekly CRM for 12 weeks. CRM results in participants who develop occlusion, infection or clots will be compared with those who do not.

If the study finds that CRM is practical, further research could use this technique to try to prevent problems before they occur.

Objectives

To describe the feasibility of weekly CRM in children and adolescents treated at St. Jude.
To describe patient and caregiver adherence with weekly CRM in children and adolescents treated at St. Jude.
To explore the correlation between results of CRM and catheter occlusion or dysfunction.

Eligibility

Participant is receiving treatment for any disease at St. Jude.
Participant is age ≥ 5 years to < 25 years.
Participant has single or double lumen tunneled CVAD (ports not eligible).
Participant anticipates being present weekly at St. Jude for at least 12 weeks.
Participant’s treating clinician does not plan to remove CVAD within 12 weeks.
Participant does not have expected survival less than 12 weeks.
Participant has not been previously enrolled in the CaRMA study or had past catheter resistance monitoring.

Principal Investigator

Joshua Wolf, MBBS

The above information is intended to provide only a basic description about a research protocol that may be currently active at St. Jude. The details made available here may not be the most up-to-date information on protocols used by St. Jude. To receive full details about a protocol and its status and or use at St. Jude, a physician must contact St. Jude directly.

Print Email This Article